ArticleEndocrine, metabolic & immune disorders drug targets2026
Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure - A Randomized Controlled Trial.
Laxmi Sankalpa Bhaganagarapu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.